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Background. β-alassemia is a common inherited hemolytic disorder in Palestine. Red blood cell (RBC) transfusion is the principal 
treatment but it may cause RBC alloimmunization. is study was conducted to determine the prevalence and characteristics of 
RBC alloimmunization among thalassemic patients in northern governorates of Palestine. Methods. A prospective multicenter 
observational study was conducted in the thalassemia transfusion centers in the northern governorates of Palestine. e study 
included 215 thalassemia patients who received regular blood transfusions. Clinical and transfusion records of patients were 
examined. Antibody screening and identication was conducted using the microcolum gel technique. Results. Two hundred een 
patients were included in the study. More than half (52.1%) of the patients were males. e median age of patients was 18 years 
(range: 12–24 years). e most frequent blood group was A (40.5%). Alloantibodies were detected in 12.6% of patients. Anti-D 
(33.3%), anti-K (25.9%) and anti-E (14.8%) were the most commonly isolated antibodies. ere was no association between age, 
sex, starting age of transfusion, number of transfused units, history of splenectomy and alloimmunization. Conclusions. Anti-Rh 
and anti-K antibodies were common among this cohort of patients. Age, sex, starting age of transfusion, number of transfused units, 
and history of splenectomy could not predict the occurrence of alloimmunization.
1. Introduction
Beta thalassemia  (β-thalassemia) is the most common inher-
ited hemolytic disorder caused by partial or complete defect 
in globin chain [1, 2]. Patients with β-thalassemia-major need 
regular blood transfusions throughout life. Blood is usually 
administered every 2–5 weeks in order to maintain the hemo-
globin level between 9.5 and 10.5 g/dl [3, 4]. 
Alloimmunization to red cell antigens is one of the impor-
tant complications of chronic blood transfusion in addition 
to iron overload and transfusion-transmitted infections [5, 6]. 
It can complicate transfusion therapy by causing delayed trans-
fusion reactions and di¡culties in nding compatible blood 
which may lead to increased morbidity and mortality in trans-
fusion-dependent patients [7–9]. 
Alloimmunization rates among multiply-transfused thal-
assemia patients range from 2.5% to 42% in di£erent regions 
of the world. e most common RBCs alloantibodies reported 
were ones against the Rhesus (Rh) and Kell antigens [10, 11]. 
ere is only one previously published report about alloim-
munization in multiply-transfused patients in Palestine. 
Samarah et al. reported the frequency of alloimmunization 
among sickle cell disease patients (7.76%) and the most fre-
quent antibody was anti-K followed by anti-E antibodies [12]. 
e objectives of this study were to [1] assess alloimmu-
nization among thalassemia patients in the northern gover-
norates of Palestine, [2] determine the specicity of detected 
antibodies, and [3] to assess the possible association between 
previously reported risk factors and the development of 
alloimmunization.
Hindawi
Advances in Hematology
Volume 2019, Article ID 3295786, 5 pages
https://doi.org/10.1155/2019/3295786
Advances in Hematology2
2. Methods
A prospective multicenter observational study was conducted 
in all thalassemia transfusion centers in the northern gover-
norates of Palestine (West Bank). Palestine consists of north-
ern and southern governorates (e West Bank and Gaza Strip, 
respectively).
3. Patients
e total number of transfusion–dependent thalassemic 
patients in the northern governorates is 500 (verbal commu-
nication from the TPFS–Palestine). In total, 215 thalassemic 
patients (β-thalassemia major and β-thalassemia intermedia) 
were conveniently selected and evaluated. Transfusion-
dependent patients who received at least 10 blood transfu-
sions, of any age or gender were included. Multiply transfused 
patients with known connective tissue disease or any other 
autoimmune diseases were excluded.
4. Data Collection
Demographic and clinical information such as age, gender, 
status of the spleen, age of starting transfusion and number of 
transfused units were obtained directly from the participants 
(or their legal guardians) or from their medical les.
5. Laboratory Methods
Blood samples were collected from all patients. Plasma was 
screened for the presence of alloantibodies by using commer-
cial three-cell panel (ID-Diacell I-II-II, Bio-Rad, Switzerland). 
e antibody specicity of all positive samples was determined 
using a commercial 11-cell identication panel (ID-DiaPanel, 
Bio-Rad, Switzerland).
6. Statistical Analysis
Statistical analysis was performed using the Statistical Package 
for the Social Science (SPSS) soware (version 23.0; SPSS Inc., 
Chicago, IL, USA). Analysis included descriptive statistics, 
frequency distribution, mean, and standard deviation calcu-
lations. e relationship between alloimmunization and age, 
starting age of transfusion, and number of transfusions was 
assessed by Mann–Whitney U test. Chi-Square or Fisher’s 
exact test was used to assess the association between gender 
and splenectomy and risk of alloimmunization. All reported 
푝 values are two-sided, with a priori signicance level of 0.05.
7. Ethical Considerations
Informed consent was obtained from patients or their legal 
guardians. e study was approved by Institutional Review 
Board committee at An-Najah National University, the 
research ethics committee at Al-Quds University and the 
Palestine Ministry of Health.
8. Results
8.1. Patient Characteristics. During the study period, 215 
patients were interviewed. ere were 112 (52.1%) male 
and 103 (47.9) female patients (Table 1). e mean age was 
19.02 ± 10.2 with a range from 2 to 70 years (Table 2). One 
hundred ninety-two patients (89.3%) were Rh(D) positive. 
e most frequent blood type was A (87; 40.5%) followed 
by O (81; 37.7%), B (35; 16.3%), and AB (12; 5.6%). One 
Table 1: Patients’ characteristics.
Variable Frequency Percentage
Gender
Male 112 52.1
Female 103 47.9
Diagnosis
Beta thalassemia major 195 90.7
Beta thalassemia intermedia 20 9.3
Blood group
A 87 40.5
B 35 16.3
O 81 37.7
AB 12 5.6
Rh (D)
Positive 192 89.3
Negative 23 10.7
Splenectomy
Yes 102 47.4
No 113 52.6
Antibody screening
Positive 27 12.6
Negative 188 87.4
Table 2: Transfusion history.
Mean ± SD Range
Age 19.02 ± 10.2 2–70
Transfusion starting age (month) 16.55 ± 27 1–300
Number of transfusions 158.8 ± 144.2 10–676
Table 3: Antibody specicity.
Type 푛 (%)
Anti-D 9 (33.3)
Anti-K 7 (25.9)
Anti-E 4 (14.8)
Anti-C 1 (3.7)
Anti-Kpa 1 (3.7)
Anti-Jka 1 (3.7)
Anti-E & anti-K 1 (3.7)
Anti-E & anti-Jka 1 (3.7)
Anti-C & anti-D 1 (3.7)
Anti-E, anti-Jka & anti-K 1 (3.7)
Total 27 (100)
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hundred ninety-ve patients (90.7%) had β-thalassemia 
major and twenty (9.3%) had β-thalassemia intermedia. 
Less than half (102; 47.4%) of the patients had their 
spleen removed (Table 1). e mean age of starting blood 
transfusion was 16.55 ± 27 years with a range of 1 month 
to 25 years. e mean number of received blood units was 
158.8 ± 144.2 with a range of 10–676 units of packed red 
blood cells (Table 2).
8.2. Alloantibody Screening and Specicity. Twenty-seven 
patients (12.6%) were alloimmunized. Twenty-three patients 
had a single alloantibody (85.2%) and four patients (14.8%) 
had multiple antibodies each (three patients had two 
antibodies each and one had three antibodies). e most 
frequent antibody was anti-D (9; 33.3%) followed by anti-K 
(7; 25.9%), anti-E (4; 14.8%) and anti-Kpa, anti-C, anti-Jka (1; 
3.7% each) (Table 3).
8.3. Assessment of Predictors for Alloimmunization. Age of 
patients, starting age of transfusion, number of transfused 
blood units, gender, and splenectomy were not signicantly 
di£erent among alloimmunized and nonalloimmunized 
patients (Table 4).
9. Discussion
is study was conducted to determine the frequency and 
specicity of alloantibodies among transfusion-dependent 
thalassemia patients in the northern governorates. On the 
other hand, we assessed the association of previously reported 
risk factors and the development of alloimmunization in our 
cohort.
is is the rst study to assess the frequency of alloanti-
bodies among thalassemia patients in Palestine. e rate of 
alloamunization was 12.6%. Higher frequency of alloimmu-
nization was reported from the province of Alexandria in 
Egypt (42.5%) [11], Taiwan (37%) [13], Kuwaiti Arabs (30%) 
[14], Saudi Arabia (22.06%) [15], Egypt (22.8%, 19.5% in lim-
ited donor program) [16], India (18.8%) [17] and Iran (17.9%, 
16.3%); [18,19].
Other studies reported lower frequency of alloimmuniza-
tion among transfusion-dependent thalassemia patients. 
Albania (11.8%); [20], Oman (9.3); [21], Malaysia (8.6%); [8], 
Pakistan (8.6%); [22], Jammu region in India (8.5%); [23], 
Fayoum province in Egypt (7.98%); [24], Tunis (7.7%); [25], 
southern Iran (5.3%); [26], Iraqi Kurdistan (4.5%); [27] and 
Karachi-Pakistan (3.75%); [28].
e most frequent alloantibodies were anti-D, anti-K and 
anti-E (33.3%, 25.9%, and 14.8% respectively). is nding is 
similar to those reported in Egypt, India, and Pakistan, where 
antibodies against the Rh-system and Kell system antigens [22, 
27, 29, 30] were the most frequent. In a study done by Ameen 
et al. [14], it was found that alloantibodies against antigens 
from the Kell-system are the most common alloantibodies 
followed by those against the Rh-system in alloimmunized 
transfusion-dependent Arab thalassemia patients in Kuwait, 
where anti-K was the most common followed by anti-E [14]. 
Moreover, Karimi et al. [26] and Davari in Iran [19] reported 
that alloantibodies belonging to the Kell-system were the most 
common alloantibodies. A lower anti-K frequency of 0.53% 
was reported in Fayoum, Egypt [24]. 
Predictors of alloimmunization among multiply trans-
fused patients are still debatable. Our study showed no signif-
icant association with age and this is in agreement with 
Al-Mousawi et al. [27] and Elhence et al. [31]. On the other 
hand Al-Riyami et al. from Oman reported a signicant asso-
ciation between age and alloimmunization [21]. 
Alloimmunization in splenectomized patients in our 
study was not statistically di£erent from nonsplectomized 
patients. Several studies reported insignicant association 
between splenectomy and alloimmunization [21, 26, 27, 
30, 31]. Other studies reported a signicant association 
[24, 29, 32].
Age at initiation of transfusion was not signicantly dif-
ferent among alloimmunized and non-alloimmunized 
patients. is is in agreement with Karimi et al., Amin et al., 
and Elhence et al. [18, 26, 31]. Other reports showed a signif-
icant association [24, 27].
Contrary to other reports [21, 23, 26, 29, 32], we did not 
nd a signicant association between the numbers of trans-
fused blood units the development of alloimmunization and 
this is in agreement with Al-Mousawi et al. [27].
Similar to our study, few reports did not nd a signicant 
relationship between alloimmunization and gender [21, 23, 
27]. Other reports found female gender [24, 33] or male [29] 
as a risk factor for alloimmunzion.
Table 4: Contribution of potential of risk factors to alloimmunization.
Variable Alloimmunized median (Q1–Q3) or 푛 (%) Nonalloimmunized median (Q1–Q3) or 푛 (%) 푝-value
Age (years) 18 (12–24) 18 (12–24) 0.832
Transfusion starting age (month) 12 (6–12) 12 (5.3–15.5) 0.875
Number of transfusions 107 (71–329) 102 (68–200) 0.42
Gender
Male 10 (37.0) 102 (54.3) 0.103
Female 17 (63.0) 86 (45.7)
History of splenectomy
Yes 11 (40.7) 91 (48.4) 0.539
No 16 (59.3) 97 (51.6)
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Asian Journal of Transfusion Science, vol. 10, no. 1, pp. 88–92, 
2016.
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G. Vyshka, “Frequency and specificity of red cell antibodies 
in thalassemia patients in Albania,”  International Journal of 
Laboratory Hematology, vol. 37, no. 4, pp. 569–574, 2015.
[21]  A. Z. Al-Riyami, A. Al-Muqbali, S. Al-Sudiri et al., “Risks of 
red blood cell alloimmunization in transfusion-dependent 
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10. Limitations of the Study
e incidence of thalassemia in Palestine is dwindling and this 
is due to the premarital screening program enforced by the 
Palestine Ministry of Health for beta thalassemia carriers and 
discouraging marriage between carriers. Clinical data were 
collected from a computerized system in the Palestinian 
Ministry of Health, but some data such as age of starting trans-
fusion, transfusion frequency and number of transfused units 
was unavailable. erefore, age of starting transfusion and 
transfusion frequency were estimated by patients or guardians 
and the number of transfused units was estimated by calcula-
tions from the age of starting transfusion and transfusion 
frequency.
11. Conclusions
e high frequency of anti-D antibodies highlights the need 
to implement strict quality control programs in the local blood 
banks to test for weak D positive antigens. Red cell alloimmu-
nization in transfusion dependent thalassemia patients can be 
minimized by phenotyping for Rh and Kell system.
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